+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Recombinant Proteins Market by Product, Services, End-User, Function - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 185 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 5592125
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Recombinant Proteins Market grew from USD 5.05 billion in 2023 to USD 5.80 billion in 2024. It is expected to continue growing at a CAGR of 14.51%, reaching USD 13.04 billion by 2030.

Recombinant proteins are proteins engineered through recombinant DNA technology, involving the insertion of DNA encoding a specific protein into a host organism to produce the desired protein. The necessity of recombinant proteins spans multiple industries including pharmaceuticals, agriculture, biotechnology, and research. They play a critical role in the development of therapeutic drugs, vaccines, and diagnostics, and are integral in producing hormones, antibodies, and enzymes. The end-use scope encompasses pharmaceutical manufacturers, research institutions, and agricultural and industrial companies. Key influencing growth factors include advancements in biotechnology, increasing demand for biologics, and the growing prevalence of chronic diseases requiring novel therapeutic solutions. The latest opportunities lie in personalized medicine and developing drugs for rare diseases, as these areas are expected to drive the demand for recombinant proteins with specific applications. Strategic recommendations include investing in biomanufacturing technologies such as continuous processing and single-use systems to meet evolving demands efficiently.

However, the market faces limitations like stringent regulatory requirements, high production costs, and technical complexities in the synthesis and purification processes, which might hinder growth. Challenges also stem from the ethical concerns surrounding genetic engineering and biosafety issues. Despite these roadblocks, the market's nature is dynamic and innovation-centric, with considerable attention paid to improving efficiency and scale of protein production. Opportunities for innovation and research include gene editing technologies like CRISPR for enhanced protein yields, development of cell-free protein synthesis systems, and exploring new host organisms for expression. There is also potential in optimizing downstream processing techniques and expanding applications beyond traditional markets, such as in environmental science and food production. By addressing these challenges and seizing opportunities in areas such as cost reduction strategies and regulatory navigation, businesses can achieve sustainable growth and maintain a competitive edge in the recombinant protein market.

Understanding Market Dynamics in the Recombinant Proteins Market

The Recombinant Proteins Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Rising focus on personalized medicine & protein therapeutics in the consumers
    • High prevalence of infectious & chronic diseases among geriatric population and children
    • Surging inclination of demand toward biologics and biosimilars proteins
  • Market Restraints
    • Concerns regarding time consumption coupled with high costs & maintenance of recombinant protein
  • Market Opportunities
    • Increasing focus on biomarker discovery and surging investments recombinant protein development
    • Growing potential for recombinant protein in animal reproduction, feed efficiency, and health
  • Market Challenges
    • Availability of alternative products and several issues in production

Exploring Porter’s Five Forces for the Recombinant Proteins Market

Porter’s Five Forces framework further strengthens the insights of the Recombinant Proteins Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Recombinant Proteins Market

External macro-environmental factors deeply influence the performance of the Recombinant Proteins Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Recombinant Proteins Market

The Recombinant Proteins Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Recombinant Proteins Market

The Recombinant Proteins Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Key Company Profiles

The report delves into recent significant developments in the Recombinant Proteins Market, highlighting leading vendors and their innovative profiles. These include Takara Bio Inc., GeoVax Labs, Inc., Takeda Pharmaceutical Company Limited, LenioBio GmbH, Sino Biological, Inc., Sanofi S.A., Bio-Rad Laboratories, Inc., R&D Systems, Inc. by Bio-Techne Corporation, Proteos, Inc., BPS Bioscience, Inc., Proteintech Group, Inc., BioLegend, Inc. by PerkinElmer, Inc., Thermo Fisher Scientific, Inc., Miltenyi Biotec B.V. & Co. KG, Fortis Life Sciences LLC, Sartorius AG, Bristol-Myers Squibb Company, Creative BioMart Inc., Biogen Inc., Abnova Corporation, Hzymes Biotech, Merck KGaA, Novartis AG, Agilent Technologies, Inc., Lonza Group AG, SK bioscience, Eli Lilly and Company, Johnson & Johnson Services, Inc., Bhat Bio-tech India Private Limited, GenScript Biotech Corporation, Marin Biologic Laboratories, Inc., Meridian Bioscience, Inc. by SD Biosensor Inc., ProMab Biotechnologies, Inc., Abcam PLC, Laurus Labs Limited, Biologics International Corp, Croyez Bioscience Co., Ltd., Enzo Life Sciences, Inc., and Selvita S.A..

Market Segmentation & Coverage

This research report categorizes the Recombinant Proteins Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Product
    • Adhesion Molecules & Receptors
    • Growth Factors & Chemokines
    • Immune Response Proteins
    • Kinase Proteins
    • Membrane Proteins
    • Recombinant Metabolic Enzymes
    • Regulatory Proteins
    • Structural Proteins
  • Services
    • Cloning
    • Expression
    • Purification
  • End-User
    • Academic Research Institutes
    • Contract Research Organizations & Contract Manufacturing Organizations
    • Pharmaceutical & Biopharmaceutical Companies
  • Function
    • Diagnostics
    • Drug Discovery & Development
      • Biologics
      • Cell & Gene Therapy
      • Vaccines
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising focus on personalized medicine & protein therapeutics in the consumers
5.1.1.2. High prevalence of infectious & chronic diseases among geriatric population and children
5.1.1.3. Surging inclination of demand toward biologics and biosimilars proteins
5.1.2. Restraints
5.1.2.1. Concerns regarding time consumption coupled with high costs & maintenance of recombinant protein
5.1.3. Opportunities
5.1.3.1. Increasing focus on biomarker discovery and surging investments recombinant protein development
5.1.3.2. Growing potential for recombinant protein in animal reproduction, feed efficiency, and health
5.1.4. Challenges
5.1.4.1. Availability of alternative products and several issues in production
5.2. Market Segmentation Analysis
5.2.1. Product: Significant use of adhesion molecules & receptors for research purposes
5.2.2. Services: Expression services focus on high yields and compatibility with target protein characteristics
5.2.3. End-User: Extensive utilization of recombinant proteins in pharmaceutical and biopharmaceutical companies
5.2.4. Function: Potential demand of recombinant proteins for drug discovery & development
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Recombinant Proteins Market, by Product
6.1. Introduction
6.2. Adhesion Molecules & Receptors
6.3. Growth Factors & Chemokines
6.4. Immune Response Proteins
6.5. Kinase Proteins
6.6. Membrane Proteins
6.7. Recombinant Metabolic Enzymes
6.8. Regulatory Proteins
6.9. Structural Proteins
7. Recombinant Proteins Market, by Services
7.1. Introduction
7.2. Cloning
7.3. Expression
7.4. Purification
8. Recombinant Proteins Market, by End-User
8.1. Introduction
8.2. Academic Research Institutes
8.3. Contract Research Organizations & Contract Manufacturing Organizations
8.4. Pharmaceutical & Biopharmaceutical Companies
9. Recombinant Proteins Market, by Function
9.1. Introduction
9.2. Diagnostics
9.3. Drug Discovery & Development
9.3.1. Biologics
9.3.2. Cell & Gene Therapy
9.3.3. Vaccines
10. Americas Recombinant Proteins Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Recombinant Proteins Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Recombinant Proteins Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
13.3.1. iTolerance and Northway Biotech Form Manufacturing Pact for Fusion Protein
13.3.2. Biovian Invests Over EUR 50M in Manufacturing Facility in Finland
13.3.3. Fortis Life Sciences acquires International Point of Care
13.3.4. Curia Expands Cell Line Development Offering with CHOZN Platform
13.3.5. Future Fields raises USD 11.2 million to scale up fruit flies for recombinant protein production
13.3.6. Merck’s Biodevelopment Centre Expansion, Martillac, France
13.3.7. Shenandoah Biotechnology Introduces Expanded Range of CTGrade Recombinant Proteins Manufactured Following cGMP Practices
13.3.8. Fujifilm to Acquire Shenandoah Biotechnology, Leading Manufacturer of Recombinant Proteins
13.3.9. Thermo Fisher Scientific Completes Acquisition of PeproTech, engaged in Recombinant Proteins
List of Figures
FIGURE 1. RECOMBINANT PROTEINS MARKET RESEARCH PROCESS
FIGURE 2. RECOMBINANT PROTEINS MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
FIGURE 7. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2023 VS 2030 (%)
FIGURE 9. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 11. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2023 VS 2030 (%)
FIGURE 13. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 15. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. UNITED STATES RECOMBINANT PROTEINS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 17. UNITED STATES RECOMBINANT PROTEINS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. ASIA-PACIFIC RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. ASIA-PACIFIC RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. RECOMBINANT PROTEINS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 23. RECOMBINANT PROTEINS MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. RECOMBINANT PROTEINS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. RECOMBINANT PROTEINS MARKET DYNAMICS
TABLE 7. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY ADHESION MOLECULES & RECEPTORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY GROWTH FACTORS & CHEMOKINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY IMMUNE RESPONSE PROTEINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY KINASE PROTEINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY MEMBRANE PROTEINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY RECOMBINANT METABOLIC ENZYMES, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY REGULATORY PROTEINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY STRUCTURAL PROTEINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY CLONING, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY EXPRESSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY PURIFICATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS & CONTRACT MANUFACTURING ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY CELL & GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 31. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 37. ARGENTINA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 38. ARGENTINA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 39. ARGENTINA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 40. ARGENTINA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 41. ARGENTINA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 42. BRAZIL RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 43. BRAZIL RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 44. BRAZIL RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 45. BRAZIL RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 46. BRAZIL RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 47. CANADA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 48. CANADA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 49. CANADA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 50. CANADA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 51. CANADA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 52. MEXICO RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 53. MEXICO RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 54. MEXICO RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 55. MEXICO RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 56. MEXICO RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES RECOMBINANT PROTEINS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 63. ASIA-PACIFIC RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 64. ASIA-PACIFIC RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 65. ASIA-PACIFIC RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 66. ASIA-PACIFIC RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 67. ASIA-PACIFIC RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 68. ASIA-PACIFIC RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 69. AUSTRALIA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 70. AUSTRALIA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 71. AUSTRALIA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 72. AUSTRALIA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 73. AUSTRALIA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 74. CHINA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 75. CHINA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 76. CHINA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 77. CHINA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 78. CHINA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 79. INDIA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 80. INDIA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 81. INDIA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 82. INDIA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 83. INDIA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 84. INDONESIA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 85. INDONESIA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 86. INDONESIA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 87. INDONESIA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 88. INDONESIA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 89. JAPAN RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 90. JAPAN RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 91. JAPAN RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 92. JAPAN RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 93. JAPAN RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 94. MALAYSIA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 95. MALAYSIA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 96. MALAYSIA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 97. MALAYSIA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 98. MALAYSIA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 99. PHILIPPINES RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 100. PHILIPPINES RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 101. PHILIPPINES RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 102. PHILIPPINES RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 103. PHILIPPINES RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 104. SINGAPORE RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 105. SINGAPORE RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 106. SINGAPORE RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 107. SINGAPORE RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 108. SINGAPORE RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 109. SOUTH KOREA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 110. SOUTH KOREA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 111. SOUTH KOREA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 112. SOUTH KOREA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 113. SOUTH KOREA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 114. TAIWAN RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 115. TAIWAN RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 116. TAIWAN RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 117. TAIWAN RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 118. TAIWAN RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 119. THAILAND RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 120. THAILAND RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 121. THAILAND RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 122. THAILAND RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 123. THAILAND RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 124. VIETNAM RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 125. VIETNAM RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 126. VIETNAM RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 127. VIETNAM RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 128. VIETNAM RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 135. DENMARK RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 136. DENMARK RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 137. DENMARK RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 138. DENMARK RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 139. DENMARK RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 140. EGYPT RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 141. EGYPT RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 142. EGYPT RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 143. EGYPT RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 144. EGYPT RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 145. FINLAND RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 146. FINLAND RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 147. FINLAND RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 148. FINLAND RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 149. FINLAND RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 150. FRANCE RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 151. FRANCE RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 152. FRANCE RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 153. FRANCE RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 154. FRANCE RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 155. GERMANY RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 156. GERMANY RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 157. GERMANY RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 158. GERMANY RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 159. GERMANY RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 160. ISRAEL RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 161. ISRAEL RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 162. ISRAEL RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 163. ISRAEL RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 164. ISRAEL RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 165. ITALY RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 166. ITALY RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 167. ITALY RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 168. ITALY RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 169. ITALY RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 170. NETHERLANDS RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 171. NETHERLANDS RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 172. NETHERLANDS RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 173. NETHERLANDS RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 174. NETHERLANDS RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 175. NIGERIA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 176. NIGERIA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 177. NIGERIA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 178. NIGERIA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 179. NIGERIA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 180. NORWAY RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 181. NORWAY RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 182. NORWAY RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 183. NORWAY RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 184. NORWAY RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 185. POLAND RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 186. POLAND RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 187. POLAND RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 188. POLAND RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 189. POLAND RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 190. QATAR RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 191. QATAR RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 192. QATAR RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 193. QATAR RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 194. QATAR RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 195. RUSSIA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 196. RUSSIA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 197. RUSSIA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 198. RUSSIA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 199. RUSSIA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 200. SAUDI ARABIA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 201. SAUDI ARABIA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 202. SAUDI ARABIA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 203. SAUDI ARABIA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 204. SAUDI ARABIA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 205. SOUTH AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 206. SOUTH AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 207. SOUTH AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 208. SOUTH AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 209. SOUTH AFRICA RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 210. SPAIN RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 211. SPAIN RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 212. SPAIN RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 213. SPAIN RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 214. SPAIN RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 215. SWEDEN RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 216. SWEDEN RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 217. SWEDEN RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 218. SWEDEN RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 219. SWEDEN RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 220. SWITZERLAND RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 221. SWITZERLAND RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 222. SWITZERLAND RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 223. SWITZERLAND RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 224. SWITZERLAND RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 225. TURKEY RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 226. TURKEY RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 227. TURKEY RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 228. TURKEY RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 229. TURKEY RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 230. UNITED ARAB EMIRATES RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 231. UNITED ARAB EMIRATES RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 232. UNITED ARAB EMIRATES RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 233. UNITED ARAB EMIRATES RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 234. UNITED ARAB EMIRATES RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 235. UNITED KINGDOM RECOMBINANT PROTEINS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 236. UNITED KINGDOM RECOMBINANT PROTEINS MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 237. UNITED KINGDOM RECOMBINANT PROTEINS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 238. UNITED KINGDOM RECOMBINANT PROTEINS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 239. UNITED KINGDOM RECOMBINANT PROTEINS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 240. RECOMBINANT PROTEINS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 241. RECOMBINANT PROTEINS MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Recombinant Proteins market, which are profiled in this report, include:
  • Takara Bio Inc.
  • GeoVax Labs, Inc.
  • Takeda Pharmaceutical Company Limited
  • LenioBio GmbH
  • Sino Biological, Inc.
  • Sanofi S.A.
  • Bio-Rad Laboratories, Inc.
  • R&D Systems, Inc. by Bio-Techne Corporation
  • Proteos, Inc.
  • BPS Bioscience, Inc.
  • Proteintech Group, Inc.
  • BioLegend, Inc. by PerkinElmer, Inc.
  • Thermo Fisher Scientific, Inc.
  • Miltenyi Biotec B.V. & Co. KG
  • Fortis Life Sciences LLC
  • Sartorius AG
  • Bristol-Myers Squibb Company
  • Creative BioMart Inc.
  • Biogen Inc.
  • Abnova Corporation
  • Hzymes Biotech
  • Merck KGaA
  • Novartis AG
  • Agilent Technologies, Inc.
  • Lonza Group AG
  • SK bioscience
  • Eli Lilly and Company
  • Johnson & Johnson Services, Inc.
  • Bhat Bio-tech India Private Limited
  • GenScript Biotech Corporation
  • Marin Biologic Laboratories, Inc.
  • Meridian Bioscience, Inc. by SD Biosensor Inc.
  • ProMab Biotechnologies, Inc.
  • Abcam PLC
  • Laurus Labs Limited
  • Biologics International Corp
  • Croyez Bioscience Co., Ltd.
  • Enzo Life Sciences, Inc.
  • Selvita S.A.

Methodology

Loading
LOADING...

Table Information